US5208020A
(en)
*
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
JP4780633B2
(ja)
|
1999-06-25 |
2011-09-28 |
イムノゲン インコーポレーティッド |
抗−ErbB抗体−メイタンシノイド複合体を用いた治療方法
|
EP2289549A3
(en)
|
1999-10-01 |
2011-06-15 |
Immunogen, Inc. |
Immunoconjugates for treating cancer
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
US6333410B1
(en)
*
|
2000-08-18 |
2001-12-25 |
Immunogen, Inc. |
Process for the preparation and purification of thiol-containing maytansinoids
|
US20110313230A1
(en)
|
2001-05-11 |
2011-12-22 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
US20050107595A1
(en)
*
|
2001-06-20 |
2005-05-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
ES2372321T3
(es)
|
2001-06-20 |
2012-01-18 |
Genentech, Inc. |
Composiciones y métodos para el diagnóstico y tratamiento de un tumor de pulmón.
|
US7803915B2
(en)
*
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
US20040235068A1
(en)
*
|
2001-09-05 |
2004-11-25 |
Levinson Arthur D. |
Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
|
EP2143438B1
(en)
|
2001-09-18 |
2011-07-13 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumors
|
US20110045005A1
(en)
|
2001-10-19 |
2011-02-24 |
Craig Crowley |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
MXPA04006554A
(es)
|
2002-01-02 |
2005-03-31 |
Genentech Inc |
Composiciones y metodos para diagnostico y tratamiento de tumor.
|
KR20040101502A
(ko)
|
2002-04-16 |
2004-12-02 |
제넨테크, 인크. |
종양의 진단 및 치료 방법 및 이를 위한 조성물
|
US20090068178A1
(en)
*
|
2002-05-08 |
2009-03-12 |
Genentech, Inc. |
Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
|
WO2004015119A2
(en)
*
|
2002-08-08 |
2004-02-19 |
Smithkline Beecham Corporation |
Methods for the isolation and purification of ansamitocins
|
US7432088B2
(en)
*
|
2003-05-08 |
2008-10-07 |
Immunogen Inc. |
Methods for the production of ansamitocins
|
EP1633784B1
(en)
|
2003-05-09 |
2011-07-13 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
US8088387B2
(en)
*
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
SI1651162T1
(sl)
|
2003-05-20 |
2016-02-29 |
Immunogen, Inc. |
Izboljšani citotoksični agenti, ki vsebujejo nove majtanzinoide
|
KR100835786B1
(ko)
|
2003-07-08 |
2008-06-09 |
제넨테크, 인크. |
Il-17a/f 이종 폴리펩티드 및 그의 치료 용도
|
JP2007501011A
(ja)
*
|
2003-08-01 |
2007-01-25 |
ジェネンテック・インコーポレーテッド |
制限多様性配列を有する結合型ポリペプチド
|
NZ578351A
(en)
|
2003-11-17 |
2012-01-12 |
Genentech Inc |
Compositions and methods for the treatment of tumor of hematopoietic origin using CD22 TAHO polypeptides
|
EP1718677B1
(en)
|
2003-12-19 |
2012-04-18 |
Genentech, Inc. |
Monovalent antibody fragments useful as therapeutics
|
EP2286844A3
(en)
*
|
2004-06-01 |
2012-08-22 |
Genentech, Inc. |
Antibody-drug conjugates and methods
|
KR101254815B1
(ko)
|
2004-07-20 |
2013-09-03 |
제넨테크, 인크. |
안지오포이에틴-유사 4 단백질의 저해제, 배합물, 그의용도
|
JP5226308B2
(ja)
|
2004-07-26 |
2013-07-03 |
ジェネンテック, インコーポレイテッド |
肝細胞増殖因子活性化を制御するための方法及び組成物
|
CA2486285C
(en)
*
|
2004-08-30 |
2017-03-07 |
Viktor S. Goldmakher |
Immunoconjugates targeting syndecan-1 expressing cells and use thereof
|
PL2990422T3
(pl)
*
|
2004-09-03 |
2018-11-30 |
Genentech, Inc. |
Humanizowani antagoniści anty-beta7 i ich zastosowania
|
DK1791565T3
(en)
|
2004-09-23 |
2016-08-01 |
Genentech Inc |
Cysteingensplejsede antibodies and conjugates
|
EP2230517A1
(en)
|
2005-01-07 |
2010-09-22 |
Diadexus, Inc. |
OVR110 antibody compositions and methods of use
|
EP1853322B1
(en)
|
2005-02-11 |
2014-06-25 |
ImmunoGen, Inc. |
Process for preparing maytansinoid antibody conjugates
|
US20110166319A1
(en)
*
|
2005-02-11 |
2011-07-07 |
Immunogen, Inc. |
Process for preparing purified drug conjugates
|
US7858843B2
(en)
|
2005-06-06 |
2010-12-28 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
WO2007021423A2
(en)
|
2005-08-15 |
2007-02-22 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
JP5350792B2
(ja)
|
2005-08-24 |
2013-11-27 |
イムノゲン インコーポレーティッド |
メイタンシノイド(maytansinoid)抗体複合体の調製方法
|
US8679490B2
(en)
|
2005-11-07 |
2014-03-25 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
|
ZA200804162B
(en)
|
2005-11-21 |
2009-12-30 |
Genentech Inc |
Novel gene disruptions, compositions and methods relating thereto
|
WO2007064919A2
(en)
*
|
2005-12-02 |
2007-06-07 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
KR101453570B1
(ko)
|
2005-12-02 |
2014-10-22 |
제넨테크, 인크. |
Il-22 및 il-22r에 결합하는 항체를 포함하는,사이토카인 신호 전달과 관련된 질환 및 장애 치료용조성물 및 치료 방법
|
US8957187B2
(en)
*
|
2005-12-02 |
2015-02-17 |
Genentech, Inc. |
Binding polypeptides and uses thereof
|
ES2535856T3
(es)
|
2005-12-15 |
2015-05-18 |
Genentech, Inc. |
Métodos y composiciones para dirigirse a la poliubiquitina
|
AU2007248444B2
(en)
|
2006-01-05 |
2012-10-25 |
Genentech, Inc. |
Anti-EphB4 antibodies and methods using same
|
KR101459160B1
(ko)
|
2006-01-20 |
2014-11-19 |
제넨테크, 인크. |
항-ephrinb2 항체 및 그의 사용 방법
|
JP2009527227A
(ja)
|
2006-02-17 |
2009-07-30 |
ジェネンテック・インコーポレーテッド |
遺伝子破壊、それに関連する組成物および方法
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
EP2007428A2
(en)
|
2006-04-05 |
2008-12-31 |
Genentech, Inc. |
Method for using boc/cdo to modulate hedgehog signaling
|
WO2008036437A2
(en)
|
2006-04-19 |
2008-03-27 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
MX2008015132A
(es)
|
2006-05-30 |
2008-12-10 |
Genentech Inc |
Anticuerpos e inmunoconjugados y sus usos.
|
CN101622276B
(zh)
|
2006-07-18 |
2015-04-22 |
赛诺菲-安万特 |
用于治疗癌症的抗epha2的拮抗抗体
|
JP2010503407A
(ja)
|
2006-09-12 |
2010-02-04 |
ジェネンテック・インコーポレーテッド |
癌の診断及び治療のための方法及び組成物
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
RU2483080C2
(ru)
|
2006-10-27 |
2013-05-27 |
Дженентек, Инк. |
Антитела и иммуноконъюгаты и их применение
|
JP5537946B2
(ja)
|
2006-11-22 |
2014-07-02 |
ブリストル−マイヤーズ スクイブ カンパニー |
Igf−irを含むチロシンキナーゼ受容体に対する改変タンパク質に基づく標的治療薬
|
EP2104513B1
(en)
|
2006-11-27 |
2015-05-20 |
diaDexus, Inc. |
Ovr110 antibody compositions and methods of use
|
ATE516814T1
(de)
|
2007-02-02 |
2011-08-15 |
Bristol Myers Squibb Co |
10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
|
CN101652389A
(zh)
|
2007-02-09 |
2010-02-17 |
健泰科生物技术公司 |
抗robo4抗体及其用途
|
CL2008000838A1
(es)
|
2007-03-23 |
2008-10-10 |
Neuraxon Inc |
Compuestos derivados de quinolina y tetrahidroquinolina, con actividad inhibidora nos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un dolor de cabeza tal como migrana, dolor cronico, desordenes del sistema nervios
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
JP5779350B2
(ja)
|
2007-03-27 |
2015-09-16 |
シー レーン バイオテクノロジーズ, エルエルシー |
抗体代替軽鎖配列を含む構築物およびライブラリー
|
PE20090321A1
(es)
|
2007-06-04 |
2009-04-20 |
Genentech Inc |
Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
|
ES2579323T3
(es)
|
2007-07-16 |
2016-08-09 |
Genentech, Inc. |
Anticuerpos anti-CD79B e inmunoconjugados y métodos de uso
|
EP2641618A3
(en)
|
2007-07-16 |
2013-10-23 |
Genentech, Inc. |
Humanized anti-CD79B antibodies and immunoconjugates and methods of use
|
RU2571515C2
(ru)
|
2007-08-29 |
2015-12-20 |
Санофи-Авентис |
Гуманизированные антитела к cxcr5, их производные и их применение
|
EP2050764A1
(en)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Novel polyvalent bispecific antibody format and uses thereof
|
US8057796B2
(en)
|
2007-11-12 |
2011-11-15 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
US20110033476A1
(en)
*
|
2007-11-12 |
2011-02-10 |
Theraclone Sciences Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
TWI580694B
(zh)
|
2007-11-30 |
2017-05-01 |
建南德克公司 |
抗-vegf抗體
|
EP2240516B1
(en)
*
|
2007-12-26 |
2015-07-08 |
Biotest AG |
Methods and agents for improving targeting of cd138 expressing tumor cells
|
HRP20140604T1
(hr)
|
2007-12-26 |
2014-09-12 |
Biotest Ag |
Sredstva koja djeluju na cd138 i njihova upotreba
|
ES2526433T3
(es)
*
|
2007-12-26 |
2015-01-12 |
Biotest Ag |
Inmunoconjugados dirigidos a CD138 y usos de los mismos
|
WO2009080831A1
(en)
*
|
2007-12-26 |
2009-07-02 |
Biotest Ag |
Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
|
ES2414804T3
(es)
|
2008-01-18 |
2013-07-22 |
Genentech, Inc. |
Métodos y composiciones que se dirigen a la poliubiquitina
|
ES2587392T3
(es)
|
2008-01-31 |
2016-10-24 |
Genentech, Inc. |
Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
|
CN102015766B
(zh)
|
2008-03-10 |
2014-07-16 |
特罗科隆科学有限公司 |
用于对巨细胞病毒感染进行治疗以及诊断的组合物以及方法
|
IL295098B1
(en)
|
2008-03-18 |
2025-08-01 |
Genentech Inc |
Combinations of trastuzumab-DM1-MCC and 5-FU for use in the treatment of ERBB2-expressing cancers
|
BRPI0906550B8
(pt)
|
2008-04-09 |
2022-01-11 |
Genentech Inc |
Anticorpo anti-tigit, usos de um anticorpo anti-tigit e métodos in vitro para estimular a interação de cd226-pvr e/ou a interação de cd96-pvr, para aumentar ou estimular a proliferação de uma célula t ou a liberação de citocinas proinflamatórias por uma célula dendrítica, para aumentar ou estimular a resposta imune de célula t e para aumentar ou estimular a produção de citocinas proinflamatórias por uma célula dendrítica
|
KR101985885B1
(ko)
|
2008-04-30 |
2019-06-04 |
이뮤노젠 아이엔씨 |
가교제 및 그 용도
|
SI2279004T1
(sl)
*
|
2008-05-16 |
2015-05-29 |
F. Hoffmann-La Roche Ag |
Uporaba biomarkerjev za ocenjevanje zdravljenja gastrointestinalnih vnetnih motenj z antagonisti beta7 integrina
|
AR071874A1
(es)
|
2008-05-22 |
2010-07-21 |
Bristol Myers Squibb Co |
Proteinas de dominio de armazon basadas en fibronectina multivalentes
|
DK2318832T3
(da)
|
2008-07-15 |
2014-01-20 |
Academia Sinica |
Glycan-arrays på PTFE-lignende aluminiumcoatede objektglas og relaterede fremgangsmåder
|
NZ591488A
(en)
|
2008-09-07 |
2012-11-30 |
Glyconex Inc |
Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
|
AR073717A1
(es)
|
2008-10-01 |
2010-11-24 |
Genentech Inc |
Anticuerpos anti-notch2 de murino y humano, y metodos de uso
|
KR20110101212A
(ko)
|
2008-12-17 |
2011-09-15 |
제넨테크, 인크. |
C형 간염 바이러스 조합 요법
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
EP3088420A1
(en)
|
2009-03-20 |
2016-11-02 |
F. Hoffmann-La Roche AG |
Bispecific anti-her antibodies
|
CN104788564A
(zh)
|
2009-03-25 |
2015-07-22 |
健泰科生物技术公司 |
抗-fgfr3抗体及其使用方法
|
NZ595574A
(en)
|
2009-04-01 |
2013-11-29 |
Genentech Inc |
Anti-fcrh5 antibodies and immunoconjugates and methods of use
|
PE20120591A1
(es)
|
2009-04-02 |
2012-05-23 |
Roche Glycart Ag |
Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
|
CA2759506A1
(en)
*
|
2009-04-23 |
2010-10-28 |
Theraclone Sciences, Inc. |
Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
|
AR076284A1
(es)
|
2009-04-29 |
2011-06-01 |
Bayer Schering Pharma Ag |
Inmunoconjugados de antimesotelina y usos de los mismos
|
JP5863640B2
(ja)
|
2009-04-29 |
2016-02-16 |
バイオ−ラッド ラボラトリーズ インコーポレーティッド |
免疫複合体の精製
|
AU2010249046A1
(en)
|
2009-05-13 |
2011-12-01 |
Sea Lane Biotechnologies, Llc |
Neutralizing molecules to influenza viruses
|
CA2762302A1
(en)
|
2009-05-20 |
2010-11-25 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
CA2761959C
(en)
|
2009-06-03 |
2018-09-11 |
Immunogen, Inc. |
Conjugation methods
|
CN102458479B
(zh)
|
2009-06-04 |
2016-07-13 |
诺华公司 |
识别IgG结合位点的方法
|
CN102802661B
(zh)
|
2009-06-22 |
2016-01-13 |
米迪缪尼有限公司 |
用于位点特异性偶联的工程改造的Fc区
|
KR20120089253A
(ko)
|
2009-07-31 |
2012-08-09 |
제넨테크, 인크. |
Bv8? 또는 g?csf?길항제를 이용한 종양 전이의 억제
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
EP2473522B1
(en)
|
2009-09-02 |
2016-08-17 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
WO2011034605A2
(en)
|
2009-09-16 |
2011-03-24 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
US20110076232A1
(en)
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
AR078470A1
(es)
|
2009-10-02 |
2011-11-09 |
Sanofi Aventis |
Anticuerpos que se unen especificamente al receptor epha2
|
TW201119677A
(en)
|
2009-10-19 |
2011-06-16 |
Genentech Inc |
Modulators of hepatocyte growth factor activator
|
RU2539772C2
(ru)
|
2009-10-22 |
2015-01-27 |
Дженентек, Инк. |
Способы и композиции для модуляции гепсином стимулирующего макрофаги белка
|
AU2010310585A1
(en)
|
2009-10-22 |
2012-05-03 |
Genentech, Inc. |
Anti-hepsin antibodies and methods using same
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
EP2496601B1
(en)
|
2009-11-05 |
2017-06-07 |
F. Hoffmann-La Roche AG |
Methods and composition for secretion of heterologous polypeptides
|
PE20121584A1
(es)
|
2009-11-30 |
2012-11-29 |
Genentech Inc |
Composiciones y metodos para el diagnostico y el tratamiento de tumores
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
JP6184695B2
(ja)
|
2009-12-04 |
2017-08-23 |
ジェネンテック, インコーポレイテッド |
多重特異性抗体、抗体アナログ、組成物、及び方法
|
US8486397B2
(en)
|
2009-12-11 |
2013-07-16 |
Genentech, Inc. |
Anti-VEGF-C antibodies and methods using same
|
WO2011079185A1
(en)
|
2009-12-23 |
2011-06-30 |
Genentech, Inc. |
Anti-bv8 antibodies and uses thereof
|
US20110159588A1
(en)
|
2009-12-30 |
2011-06-30 |
Kui Lin |
Methods for Modulating a PDGF-AA Mediated Biological Response
|
BR112012020102A2
(pt)
|
2010-02-10 |
2016-11-29 |
Immunogen Inc |
anticorpos cd20 e usos dos mesmos.
|
CA2787657A1
(en)
|
2010-02-23 |
2011-09-01 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
TW202348631A
(zh)
|
2010-02-24 |
2023-12-16 |
美商免疫遺傳股份有限公司 |
葉酸受體1抗體類和免疫共軛物類及彼等之用途
|
EP3620467A1
(en)
|
2010-03-12 |
2020-03-11 |
Debiopharm International SA |
Cd37-binding molecules and immunoconjugates thereof
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
US10338069B2
(en)
|
2010-04-12 |
2019-07-02 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
TW201742925A
(zh)
|
2010-04-23 |
2017-12-16 |
建南德克公司 |
異多聚體蛋白質之製造
|
JP2013533732A
(ja)
|
2010-05-03 |
2013-08-29 |
ジェネンテック, インコーポレイテッド |
腫瘍の診断と治療のための組成物と方法
|
JP6048973B2
(ja)
|
2010-06-03 |
2016-12-27 |
ジェネンテック, インコーポレイテッド |
抗体及びイムノコンジュゲートのイムノpetイメージング及びこれらの使用方法
|
US9000130B2
(en)
|
2010-06-08 |
2015-04-07 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
WO2012016227A2
(en)
|
2010-07-29 |
2012-02-02 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
WO2012019024A2
(en)
|
2010-08-04 |
2012-02-09 |
Immunogen, Inc. |
Her3-binding molecules and immunoconjugates thereof
|
JP2013540701A
(ja)
|
2010-08-12 |
2013-11-07 |
セラクローン サイエンシーズ, インコーポレイテッド |
抗赤血球凝集素抗体組成物およびその使用方法
|
CN103068846B9
(zh)
|
2010-08-24 |
2016-09-28 |
弗·哈夫曼-拉罗切有限公司 |
包含二硫键稳定性Fv片段的双特异性抗体
|
ES2920140T3
(es)
|
2010-08-31 |
2022-08-01 |
Theraclone Sciences Inc |
Anticuerpos neutralizantes del virus de la inmunodeficiencia humana (VIH)
|
JP5866130B2
(ja)
|
2010-09-10 |
2016-02-17 |
アペクシジェン, インコーポレイテッド |
抗IL−1β抗体およびその使用方法
|
DK2621526T3
(en)
|
2010-09-29 |
2018-08-06 |
Agensys Inc |
ANTIBODY-PHARMACEUTICAL CONJUGATES (ADC) BINDING TO 191P4D12 PROTEINS
|
EP3828205A1
(en)
|
2010-10-01 |
2021-06-02 |
Oxford BioTherapeutics Ltd |
Anti-ror1 antibodies
|
WO2012047968A2
(en)
|
2010-10-05 |
2012-04-12 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
CN103298489A
(zh)
|
2010-10-29 |
2013-09-11 |
伊缪诺金公司 |
新型egfr结合分子及其免疫偶联物
|
BR112013010569A2
(pt)
|
2010-10-29 |
2017-07-04 |
Immunogen Inc |
moléculas de ligação de egfr não antagonísticas e imunoconjugados das mesma
|
JP5766296B2
(ja)
|
2010-12-23 |
2015-08-19 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
JP6161540B2
(ja)
|
2011-02-04 |
2017-07-12 |
ジェネンテック, インコーポレイテッド |
Fc変異体及びそれらの生産方法
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
CN103687619A
(zh)
|
2011-02-14 |
2014-03-26 |
特罗科隆科学有限公司 |
用于对流行性感冒进行治疗以及诊断的组合物以及方法
|
CA2827581A1
(en)
|
2011-03-03 |
2012-09-07 |
Apexigen, Inc. |
Anti-il-6 receptor antibodies and methods of use
|
CN103533929A
(zh)
|
2011-03-15 |
2014-01-22 |
特罗科隆科学有限公司 |
用于流行性感冒的治疗和诊断的组合物和方法
|
US20130344074A1
(en)
|
2011-03-16 |
2013-12-26 |
Sanofi |
Uses of a dual v region antibody-like protein
|
SG193997A1
(en)
|
2011-03-29 |
2013-11-29 |
Immunogen Inc |
Process for manufacturing conjugates of improved homogeneity
|
EA201991268A3
(ru)
|
2011-03-29 |
2020-01-31 |
Иммуноджен, Инк. |
Получение конъюгатов "майтансиноид-антитело" одностадийным способом
|
BR112013027829B1
(pt)
|
2011-04-29 |
2022-05-10 |
Apexigen, Inc |
Anticorpos anti-cd40 ou fragmentos de ligação aos antígenos destes, composição que compreende os ditos anticorpos e uso da dita composição para tratar ou melhorar os sintomas de câncer, doença autoimune ou doença inflamatória
|
CA2835203A1
(en)
|
2011-05-09 |
2012-11-15 |
University Of Virginia Patent Foundation |
Compositions and methods for treating cancer
|
PH12013502421A1
(en)
|
2011-05-27 |
2014-01-06 |
Glaxo Group Ltd |
Bcma (cd269/tnfrsf17) -binding proteins
|
TWI597065B
(zh)
|
2011-06-10 |
2017-09-01 |
梅爾莎納醫療公司 |
蛋白質-聚合物-藥物共軛體
|
WO2012177837A2
(en)
|
2011-06-21 |
2012-12-27 |
Immunogen, Inc. |
Novel maytansinoid derivatives with peptide linker and conjugates thereof
|
WO2013016714A1
(en)
|
2011-07-28 |
2013-01-31 |
Sea Lane Biotechnologies |
Sur-binding proteins against erbb3
|
WO2013022855A1
(en)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points and immunofiltering
|
CN103890008A
(zh)
|
2011-08-17 |
2014-06-25 |
霍夫曼-拉罗奇有限公司 |
在顽固性肿瘤中抑制血管发生
|
WO2013033069A1
(en)
|
2011-08-30 |
2013-03-07 |
Theraclone Sciences, Inc. |
Human rhinovirus (hrv) antibodies
|
CN104136461B
(zh)
|
2011-09-22 |
2021-06-08 |
安姆根有限公司 |
Cd27l抗原结合蛋白
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
CA2851534C
(en)
|
2011-10-10 |
2023-02-14 |
Xencor, Inc. |
A method for purifying antibodies
|
KR20140097205A
(ko)
|
2011-10-28 |
2014-08-06 |
제넨테크, 인크. |
흑색종을 치료하는 치료 조합물 및 방법
|
KR102027603B1
(ko)
|
2011-11-02 |
2019-10-01 |
아펙시젠, 인코포레이티드 |
항-kdr 항체 및 사용 방법
|
US9233171B2
(en)
|
2011-11-21 |
2016-01-12 |
Immunogen, Inc. |
Method of treatment of tumors that are resistant to EGFR antibody therapies by EGFR antibody cytotoxic agent conjugate
|
ES2684950T3
(es)
|
2011-12-08 |
2018-10-05 |
Biotest Ag |
Usos de inmunoconjugados dirigidos a CD138
|
EP3446707A1
(en)
|
2011-12-22 |
2019-02-27 |
i2 Pharmaceuticals, Inc. |
Surrogate binding proteins
|
US11147852B2
(en)
|
2011-12-23 |
2021-10-19 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
EP3663314A1
(en)
|
2012-01-09 |
2020-06-10 |
The Scripps Research Institute |
Humanized antibodies with ultralong cdr3s
|
CA2863224A1
(en)
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Ultralong complementarity determining regions and uses thereof
|
JP2015505537A
(ja)
|
2012-01-20 |
2015-02-23 |
シー レーン バイオテクノロジーズ, エルエルシー |
結合分子コンジュゲート
|
MX2014009565A
(es)
|
2012-02-10 |
2014-11-10 |
Genentech Inc |
Anticuerpos monocatenarios y otros heteromultimeros.
|
WO2013130093A1
(en)
|
2012-03-02 |
2013-09-06 |
Genentech, Inc. |
Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
|
SG11201405553YA
(en)
|
2012-03-08 |
2014-11-27 |
Halozyme Inc |
Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
JP6242865B2
(ja)
|
2012-05-01 |
2017-12-06 |
ジェネンテック, インコーポレイテッド |
抗pmel17抗体および免疫複合体
|
UY34813A
(es)
|
2012-05-18 |
2013-11-29 |
Amgen Inc |
Proteínas de unión a antígeno dirigidas contra el receptor st2
|
WO2014001325A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
RU2639287C2
(ru)
|
2012-06-27 |
2017-12-20 |
Ф. Хоффманн-Ля Рош Аг |
Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
|
JP6302909B2
(ja)
|
2012-08-18 |
2018-03-28 |
アカデミア シニカAcademia Sinica |
シアリダーゼの同定および画像化のための細胞透過性プローブ
|
AR092219A1
(es)
|
2012-08-23 |
2015-04-08 |
Seattle Genetics Inc |
Conjugados anticuerpo-farmaco (adc) que se unen a proteinas 158p1d7
|
RU2018122734A
(ru)
|
2012-10-04 |
2018-07-24 |
Иммуноджен, Инк. |
Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент-цитотоксический агент
|
CN110066335B
(zh)
|
2012-10-30 |
2024-04-05 |
埃派斯进有限公司 |
抗-cd40抗体及其使用方法
|
PL2922875T3
(pl)
|
2012-11-20 |
2017-08-31 |
Sanofi |
Przeciwciała anty-CEACAM5 i ich zastosowanie
|
WO2014080251A1
(en)
|
2012-11-24 |
2014-05-30 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Bcma抗原結合蛋白質
|
CA2892863C
(en)
|
2012-12-10 |
2022-03-15 |
Mersana Therapeutics, Inc. |
Polymeric scaffold based on phf for targeted drug delivery
|
US9872918B2
(en)
|
2012-12-12 |
2018-01-23 |
Mersana Therapeutics, Inc. |
Hydroxyl-polymer-drug-protein conjugates
|
CA2896248A1
(en)
|
2012-12-27 |
2014-07-03 |
Sanofi |
Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
HRP20191865T1
(hr)
|
2013-01-14 |
2020-01-10 |
Xencor, Inc. |
Novi heterodimerni proteini
|
EP2945969A1
(en)
|
2013-01-15 |
2015-11-25 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
US9920121B2
(en)
|
2013-01-25 |
2018-03-20 |
Amgen Inc. |
Antibodies targeting CDH19 for melanoma
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
CN105189552B
(zh)
|
2013-03-14 |
2019-08-02 |
基因泰克公司 |
抗b7-h4抗体和免疫缀合物
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
AU2014235474B2
(en)
|
2013-03-15 |
2017-05-25 |
Novartis Ag |
Antibody drug conjugates
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
EP2970486B1
(en)
|
2013-03-15 |
2018-05-16 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
CN105377889B
(zh)
|
2013-03-15 |
2020-07-17 |
Xencor股份有限公司 |
异二聚体蛋白
|
AU2014262566A1
(en)
|
2013-05-08 |
2015-11-12 |
Zymeworks Inc. |
Bispecific HER2 and HER3 antigen binding constructs
|
CN107513105B
(zh)
|
2013-05-30 |
2019-08-16 |
基尼克萨制药有限公司 |
制瘤素m受体抗原结合蛋白
|
EP3013365B1
(en)
|
2013-06-26 |
2019-06-05 |
Academia Sinica |
Rm2 antigens and use thereof
|
WO2014210564A1
(en)
|
2013-06-27 |
2014-12-31 |
Academia Sinica |
Glycan conjugates and use thereof
|
WO2015017146A2
(en)
|
2013-07-18 |
2015-02-05 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
AU2014290361B2
(en)
|
2013-07-18 |
2019-04-18 |
Taurus Biosciences, Llc |
Humanized antibodies with ultralong complementarity determining regions
|
EP3738611B1
(en)
|
2013-07-31 |
2025-09-03 |
BioNTech SE |
Diagnosis and therapy of cancer involving cancer stem cells
|
CA2919701A1
(en)
|
2013-08-01 |
2015-02-05 |
Agensys, Inc. |
Antibody drug conjugates (adc) that bind to cd37 proteins
|
CN104341504B
(zh)
|
2013-08-06 |
2017-10-24 |
百奥泰生物科技(广州)有限公司 |
双特异性抗体
|
US9782476B2
(en)
|
2013-09-06 |
2017-10-10 |
Academia Sinica |
Human iNKT cell activation using glycolipids with altered glycosyl groups
|
JP6282745B2
(ja)
|
2013-09-12 |
2018-02-21 |
ハロザイム インコーポレイテッド |
修飾抗上皮成長因子受容体抗体およびその使用法
|
KR20160055252A
(ko)
|
2013-09-17 |
2016-05-17 |
제넨테크, 인크. |
항-lgr5 항체의 사용 방법
|
EP4424323A3
(en)
|
2013-10-08 |
2024-11-13 |
ImmunoGen, Inc. |
Anti-folr1 immunoconjugate dosing regimens
|
SG11201602460QA
(en)
|
2013-10-11 |
2016-04-28 |
Oxford Biotherapeutics Ltd |
Conjugated antibodies against ly75 for the treatment of cancer
|
DK3054991T3
(da)
|
2013-10-11 |
2019-05-06 |
Mersana Therapeutics Inc |
Protein-polymer-lægemiddelkonjugater
|
PL3054992T3
(pl)
|
2013-10-11 |
2020-01-31 |
Asana Biosciences, Llc |
Koniugaty białko-polimer-lek
|
EP3054987B1
(en)
|
2013-10-11 |
2019-10-09 |
The United States of America, represented by the Secretary, Department of Health and Human Services |
Tem8 antibodies and their use
|
EP3066118B1
(en)
|
2013-11-06 |
2020-01-08 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
CA2930307A1
(en)
|
2013-11-13 |
2015-05-21 |
Zymeworks Inc. |
Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof
|
CA2931340A1
(en)
|
2013-12-13 |
2015-06-18 |
Genentech, Inc. |
Anti-cd33 antibodies and immunoconjugates
|
CN107106700B
(zh)
|
2013-12-16 |
2020-10-30 |
基因泰克公司 |
肽模拟化合物及其抗体-药物缀合物
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
KR20160104727A
(ko)
|
2014-01-16 |
2016-09-05 |
아카데미아 시니카 |
암의 치료 및 검출을 위한 조성물 및 방법
|
BR112016015693A2
(pt)
|
2014-01-24 |
2017-10-24 |
Genentech Inc |
método para tratar um câncer de próstata e anticorpo
|
AU2015214264B2
(en)
|
2014-02-04 |
2018-12-20 |
Curis, Inc. |
Mutant Smoothened and methods of using the same
|
EP3122757B1
(en)
|
2014-02-28 |
2023-09-06 |
Hangzhou Dac Biotech Co., Ltd |
Charged linkers and their uses for conjugation
|
CN106415244B
(zh)
|
2014-03-27 |
2020-04-24 |
中央研究院 |
反应性标记化合物及其用途
|
CR20160506A
(es)
|
2014-03-28 |
2017-03-10 |
Xencor Inc |
Anticuerpos biespecíficos que se unen a cd38 y cd3
|
TW201542594A
(zh)
|
2014-04-11 |
2015-11-16 |
Medimmune Llc |
雙特異性her2抗體
|
KR20230164192A
(ko)
|
2014-05-06 |
2023-12-01 |
제넨테크, 인크. |
포유동물 세포를 사용한 이종다량체 단백질의 생산
|
KR20170003582A
(ko)
|
2014-05-22 |
2017-01-09 |
제넨테크, 인크. |
항-gpc3 항체 및 면역접합체
|
DK3149045T3
(da)
|
2014-05-27 |
2023-03-06 |
Academia Sinica |
Sammensætninger og fremgangsmåder vedrørende universelle glycoformer til forbedret antistofeffekt
|
EP4116329A1
(en)
|
2014-05-27 |
2023-01-11 |
Academia Sinica |
Anti-her2 glycoantibodies and uses thereof
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
AU2015267047A1
(en)
|
2014-05-27 |
2017-01-05 |
Academia Sinica |
Anti-CD20 glycoantibodies and uses thereof
|
AU2015267044A1
(en)
|
2014-05-28 |
2016-12-15 |
Academia Sinica |
Anti-TNF-alpha glycoantibodies and uses thereof
|
AU2015292326A1
(en)
|
2014-07-24 |
2017-02-23 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
KR20170040249A
(ko)
|
2014-08-12 |
2017-04-12 |
노파르티스 아게 |
항-cdh6 항체 약물 접합체
|
MX2017002605A
(es)
|
2014-08-28 |
2017-05-19 |
Bioatla Llc |
Receptores de antigeno quimerico condicionalmente activos para celulas t modificadas.
|
CN106999604B
(zh)
|
2014-09-02 |
2021-08-03 |
伊缪诺金公司 |
用于配制抗体药物缀合物组合物的方法
|
AU2015315294B2
(en)
|
2014-09-08 |
2020-09-17 |
Academia Sinica |
Human iNKT cell activation using glycolipids
|
AR101848A1
(es)
|
2014-09-12 |
2017-01-18 |
Genentech Inc |
Anticuerpos de anti-b7-h4 e inmunoconjugados
|
JP6886398B2
(ja)
|
2014-09-12 |
2021-06-16 |
ジェネンテック, インコーポレイテッド |
Anti−cll−1抗体及び免疫複合体
|
JP2017531620A
(ja)
|
2014-09-12 |
2017-10-26 |
ジェネンテック, インコーポレイテッド |
システイン操作抗体及びコンジュゲート
|
MA40576B1
(fr)
|
2014-09-12 |
2020-11-30 |
Genentech Inc |
Anticorps et immunoconjugués anti-her2
|
DK3262071T3
(da)
|
2014-09-23 |
2020-06-15 |
Hoffmann La Roche |
Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
|
CN106922129B
(zh)
|
2014-10-01 |
2024-02-20 |
免疫医疗有限责任公司 |
轭合多肽的方法
|
JP6877350B2
(ja)
|
2014-11-05 |
2021-05-26 |
ジェネンテック, インコーポレイテッド |
抗fgfr2/3抗体及びその使用方法
|
RU2711930C2
(ru)
|
2014-11-19 |
2020-01-23 |
Иммуноджен, Инк. |
Способ получения конъюгатов агента, связывающегося с клетками, и цитотоксического агента
|
JP6696982B2
(ja)
|
2014-11-26 |
2020-05-20 |
ゼンコー・インコーポレイテッドXencor、 Inc. |
Cd3および腫瘍抗原に結合するヘテロ二量体抗体
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
MX2017006918A
(es)
|
2014-11-26 |
2018-01-25 |
Xencor Inc |
Anticuerpos heterodimericos que se unen a cd3 y cd38.
|
WO2016087416A1
(en)
|
2014-12-03 |
2016-06-09 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
CN114656483A
(zh)
|
2014-12-04 |
2022-06-24 |
细胞基因公司 |
生物分子共轭物
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
CA2972731A1
(en)
|
2015-01-24 |
2016-07-28 |
Chi-Huey Wong |
Cancer markers and methods of use thereof
|
EP3248005B1
(en)
|
2015-01-24 |
2020-12-09 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
US10330683B2
(en)
|
2015-02-04 |
2019-06-25 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
US10780179B2
(en)
|
2015-03-18 |
2020-09-22 |
Immunobiochem Corporation |
Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
|
WO2016165762A1
(en)
|
2015-04-15 |
2016-10-20 |
Ganymed Pharmaceuticals Ag |
Drug conjugates comprising antibodies against claudin 18.2
|
CN116063543A
(zh)
|
2015-04-24 |
2023-05-05 |
豪夫迈·罗氏有限公司 |
多特异性抗原结合蛋白
|
US10639329B2
(en)
|
2015-06-12 |
2020-05-05 |
Lentigen Technology, Inc. |
Method to treat cancer with engineered T-cells
|
EP3310813A1
(en)
|
2015-06-17 |
2018-04-25 |
Novartis AG |
Antibody drug conjugates
|
AU2015242213A1
(en)
|
2015-07-12 |
2018-03-08 |
Hangzhou Dac Biotech Co., Ltd |
Bridge linkers for conjugation of cell-binding molecules
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
HK1255141A1
(zh)
|
2015-09-17 |
2019-08-09 |
伊缪诺金公司 |
包含抗folr1免疫缀合物的治疗组合
|
US11078286B2
(en)
|
2015-09-20 |
2021-08-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their use
|
WO2017062820A1
(en)
|
2015-10-09 |
2017-04-13 |
Miltenyi Biotec Technology, Inc. |
Chimeric antigen receptors and methods of use
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
WO2017066714A1
(en)
|
2015-10-16 |
2017-04-20 |
Compugen Ltd. |
Anti-vsig1 antibodies and drug conjugates
|
EP3387013B1
(en)
|
2015-12-07 |
2022-06-08 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and psma
|
AU2017212484C1
(en)
|
2016-01-27 |
2020-11-05 |
Medimmune, Llc |
Methods for preparing antibodies with a defined glycosylation pattern
|
CA3019952A1
(en)
|
2016-02-04 |
2017-08-10 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
AU2017213858A1
(en)
|
2016-02-05 |
2018-08-16 |
Immunogen, Inc. |
Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
|
TW201808978A
(zh)
|
2016-03-08 |
2018-03-16 |
中央研究院 |
N-聚醣及其陣列之模組化合成方法
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
JP7323102B2
(ja)
|
2016-04-13 |
2023-08-08 |
オリマブス リミテッド |
抗psma抗体およびその使用
|
CA3021086C
(en)
|
2016-04-15 |
2023-10-17 |
Bioatla, Llc |
Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
|
WO2017196847A1
(en)
|
2016-05-10 |
2017-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
|
WO2017194568A1
(en)
|
2016-05-11 |
2017-11-16 |
Sanofi |
Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
|
MX394735B
(es)
|
2016-05-13 |
2025-03-24 |
Bioatla Llc |
Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
|
CN109313200B
(zh)
|
2016-05-27 |
2022-10-04 |
豪夫迈·罗氏有限公司 |
用于表征位点特异性抗体-药物缀合物的生物分析性方法
|
WO2017214182A1
(en)
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Fully human antibody targeting pdi for cancer immunotherapy
|
EP3468586B1
(en)
|
2016-06-14 |
2024-08-07 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
WO2018004338A1
(en)
|
2016-06-27 |
2018-01-04 |
Tagworks Pharmaceuticals B.V. |
Cleavable tetrazine used in bio-orthogonal drug activation
|
EP3475304B1
(en)
|
2016-06-28 |
2022-03-23 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
CA3031559A1
(en)
|
2016-08-02 |
2018-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
|
EP3494139B1
(en)
|
2016-08-05 |
2022-01-12 |
F. Hoffmann-La Roche AG |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
AU2017316663B2
(en)
|
2016-08-22 |
2024-02-22 |
CHO Pharma Inc. |
Antibodies, binding fragments, and methods of use
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
CN117298260A
(zh)
|
2016-09-02 |
2023-12-29 |
莱蒂恩技术公司 |
用DuoCAR治疗癌症的组合物和方法
|
EP3526240A1
(en)
|
2016-10-14 |
2019-08-21 |
Xencor, Inc. |
Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
|
US11278629B2
(en)
|
2016-11-02 |
2022-03-22 |
Debiopharm International, S.A. |
Methods for improving anti-CD37 immunoconjugate therapy
|
NZ752394A
(en)
|
2016-11-14 |
2021-07-30 |
Hangzhou Dac Biotech Co Ltd |
Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
|
EP4015532A1
(en)
|
2016-11-21 |
2022-06-22 |
cureab GmbH |
Anti-gp73 antibodies and immunoconjugates
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
EP3559038B1
(en)
|
2016-12-21 |
2022-12-14 |
The United States of America as represented by The Secretary Department of Health and Human Services |
Human monoclonal antibodies specific for flt3 and uses thereof
|
EP4183798A1
(en)
|
2017-01-09 |
2023-05-24 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-mesothelin immunotherapy
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
GB201703876D0
(en)
|
2017-03-10 |
2017-04-26 |
Berlin-Chemie Ag |
Pharmaceutical combinations
|
AU2018240556B2
(en)
|
2017-03-24 |
2025-02-27 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD33 immunotherapy
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
WO2018213064A1
(en)
|
2017-05-19 |
2018-11-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibody targeting tnfer2 for cancer immunotherapy
|
AR111963A1
(es)
|
2017-05-26 |
2019-09-04 |
Univ California |
Método y moléculas
|
AU2018290330A1
(en)
|
2017-06-22 |
2020-01-02 |
Mersana Therapeutics, Inc. |
Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
|
WO2019006280A1
(en)
|
2017-06-30 |
2019-01-03 |
Lentigen Technology, Inc. |
HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE
|
US11084863B2
(en)
|
2017-06-30 |
2021-08-10 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
|
WO2019005208A1
(en)
|
2017-06-30 |
2019-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
|
JP7237926B2
(ja)
|
2017-07-31 |
2023-03-13 |
レンティジェン・テクノロジー・インコーポレイテッド |
抗cd19/cd20免疫療法によりがんを処置するための組成物および方法
|
CN107446050A
(zh)
|
2017-08-11 |
2017-12-08 |
百奥泰生物科技(广州)有限公司 |
Trop2阳性疾病治疗的化合物及方法
|
US11524082B2
(en)
|
2017-08-22 |
2022-12-13 |
Purdue Research Foundation |
FBSA-based therapeutic and radioimaging conjugates targeting carbonic anhydrase positive cancers
|
CN111936510B
(zh)
|
2017-09-15 |
2024-09-27 |
莱蒂恩技术公司 |
用于用抗cd19免疫治疗来治疗癌症的组合物和方法
|
CN111629735B
(zh)
|
2017-10-16 |
2024-05-17 |
莱蒂恩技术公司 |
用于用抗cd22免疫治疗来治疗癌症的组合物和方法
|
EP3700540A4
(en)
|
2017-10-24 |
2021-11-10 |
Magenta Therapeutics, Inc. |
COMPOSITIONS AND METHODS OF DEPRODUCTION FROM CD117 + CELLS
|
CN111741757B
(zh)
|
2017-11-03 |
2023-12-19 |
莱蒂恩技术公司 |
用于用抗ror1免疫治疗来治疗癌症的组合物和方法
|
CA3082383A1
(en)
|
2017-11-08 |
2019-05-16 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-pd-1 sequences
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
EP3717022A4
(en)
|
2017-11-29 |
2021-11-10 |
Magenta Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR DEPLOYING CD5 + CELLS
|
WO2019118937A1
(en)
|
2017-12-15 |
2019-06-20 |
Juno Therapeutics, Inc. |
Anti-cct5 binding molecules and methods of use thereof
|
CA3086199A1
(en)
|
2017-12-19 |
2019-06-27 |
Xencor, Inc. |
Engineered il-2 fc fusion proteins
|
WO2019126464A2
(en)
|
2017-12-20 |
2019-06-27 |
Lentigen Technology, Inc. |
Compositions and methods for treating hiv/aids with immunotherapy
|
TW202003047A
(zh)
|
2018-03-23 |
2020-01-16 |
美商西雅圖遺傳學公司 |
包括微管蛋白破壞劑之抗體藥物結合物治療實體腫瘤之用途
|
CN112469477A
(zh)
|
2018-04-04 |
2021-03-09 |
Xencor股份有限公司 |
与成纤维细胞活化蛋白结合的异源二聚体抗体
|
KR20210010862A
(ko)
|
2018-04-18 |
2021-01-28 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도
|
CA3097741A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
AU2019262521B2
(en)
|
2018-05-04 |
2024-04-18 |
Tagworks Pharmaceuticals B.V. |
Compounds comprising a linker for increasing transcyclooctene stability
|
EP3787691A1
(en)
|
2018-05-04 |
2021-03-10 |
Tagworks Pharmaceuticals B.V. |
Tetrazines for high click conjugation yield in vivo and high click release yield
|
CA3101790A1
(en)
|
2018-05-30 |
2019-12-05 |
Debiopharm International, S.A. |
Anti-cd37 immunoconjugate dosing regimens
|
GB201809746D0
(en)
|
2018-06-14 |
2018-08-01 |
Berlin Chemie Ag |
Pharmaceutical combinations
|
MA53094A
(fr)
|
2018-07-02 |
2021-05-12 |
Amgen Inc |
Protéine de liaison à l'antigène anti-steap1
|
JP7459043B2
(ja)
|
2018-07-12 |
2024-04-01 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
親和性成熟cd22特異的モノクローナル抗体およびその使用
|
CA3107383A1
(en)
|
2018-07-23 |
2020-01-30 |
Magenta Therapeutics, Inc. |
Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
|
CN112585163B
(zh)
|
2018-08-08 |
2025-03-25 |
美国政府(由卫生和人类服务部的部长所代表) |
靶向磷脂酰肌醇蛋白聚糖-2的高亲和力单克隆抗体及其用途
|
WO2020061498A1
(en)
|
2018-09-20 |
2020-03-26 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd123 immunotherapy
|
JP7546554B2
(ja)
|
2018-09-26 |
2024-09-06 |
レンティジェン・テクノロジー・インコーポレイテッド |
抗cd19/cd22免疫療法によりがんを処置するための組成物および方法
|
MA53822A
(fr)
|
2018-10-03 |
2021-08-11 |
Xencor Inc |
Protéines de fusion fc hétérodimères d'il -12
|
JP2022513400A
(ja)
|
2018-10-29 |
2022-02-07 |
メルサナ セラピューティクス インコーポレイテッド |
ペプチド含有リンカーを有するシステイン操作抗体-薬物コンジュゲート
|
WO2020113108A1
(en)
|
2018-11-30 |
2020-06-04 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd38 immunotherapy
|
WO2020117257A1
(en)
|
2018-12-06 |
2020-06-11 |
Genentech, Inc. |
Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody
|
AU2020206308A1
(en)
|
2019-01-08 |
2021-07-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross-species single domain antibodies targeting mesothelin for treating solid tumors
|
EP3883971A1
(en)
|
2019-01-22 |
2021-09-29 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
High affinity monoclonal antibodies targeting glypican-1 and methods of use
|
CA3129106A1
(en)
|
2019-02-07 |
2020-08-13 |
Sanofi |
Use of anti-ceacam5 immunoconjugates for treating lung cancer
|
EP3693023A1
(en)
|
2019-02-11 |
2020-08-12 |
Sanofi |
Use of anti-ceacam5 immunoconjugates for treating lung cancer
|
BR112021016955A2
(pt)
|
2019-03-01 |
2021-11-23 |
Xencor Inc |
Composição, composição de ácido nucleico, composição de vetor de expressão, vetor de expressão, célula hospedeira, métodos de produção de um domínio de ligação de membro de família 3 de pirofosfatase/fosfodiesterase de ectonucleotídeo e de tratamento de um câncer, anticorpo anti-enpp3, e, anticorpo heterodimérico
|
AU2020232789A1
(en)
|
2019-03-06 |
2021-10-07 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with self-driving chimeric antigen receptors
|
BR112021022815A2
(pt)
|
2019-05-14 |
2021-12-28 |
Genentech Inc |
Métodos para tratar linfoma folicular, kits, imunoconjugados e polatuzumabe vedotina
|
CN114364801B
(zh)
|
2019-05-30 |
2024-04-19 |
莱蒂恩技术公司 |
用于用抗bcma免疫治疗来治疗癌症的组合物和方法
|
IL289094A
(en)
|
2019-06-17 |
2022-02-01 |
Tagworks Pharmaceuticals B V |
Tetrazines for increasing the speed and yield of the "click release" reaction
|
ES2981364T3
(es)
|
2019-06-17 |
2024-10-08 |
Tagworks Pharmaceuticals B V |
Compuestos para liberación clic rápida y eficiente
|
EA202290208A1
(ru)
|
2019-07-02 |
2022-03-25 |
Дзе Юнайтед Стейтс Оф Эмерика, Эз Репрезентед Бай Дзе Секретэри, Дипартмент Оф Хелт Энд Хьюман Сервисиз |
МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТ EGFRvIII, И ИХ ПРИМЕНЕНИЕ
|
EP3998083A4
(en)
|
2019-07-12 |
2023-08-23 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-MUTATION TYPE FGFR3 ANTIBODY AND USE THEREOF
|
TW202122114A
(zh)
|
2019-10-18 |
2021-06-16 |
美商建南德克公司 |
使用抗CD79b 免疫偶聯物治療彌漫性大B 細胞淋巴瘤的方法
|
US20220380471A1
(en)
|
2019-10-22 |
2022-12-01 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
High affinity nanobodies targeting b7-h3 (cd276) for treating multiple solid tumors
|
CA3161573A1
(en)
|
2019-12-12 |
2021-06-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-drug conjugates specific for cd276 and uses thereof
|
EP4138925A1
(en)
|
2020-04-24 |
2023-03-01 |
Sanofi |
Antitumor combinations containing anti-ceacam5 antibody conjugates, trifluridine and tipiracil
|
JP2023522395A
(ja)
|
2020-04-24 |
2023-05-30 |
サノフイ |
抗ceacam5抗体コンジュゲートおよびフォルフォックスを含有する抗腫瘍組み合わせ
|
TW202206109A
(zh)
|
2020-04-24 |
2022-02-16 |
法商賽諾菲公司 |
含有抗ceacam5抗體接合物與folfiri之抗腫瘤組合
|
JP2023522393A
(ja)
|
2020-04-24 |
2023-05-30 |
サノフイ |
抗ceacam5抗体コンジュゲートおよびセツキシマブを含有する抗腫瘍組み合わせ
|
BR112022021441A2
(pt)
|
2020-04-24 |
2022-12-13 |
Genentech Inc |
Métodos para tratar linfoma folicular e linfoma difuso de grandes células b e kits
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
CN116829581A
(zh)
|
2020-06-22 |
2023-09-29 |
莱蒂恩技术公司 |
用于用tslpr-cd19或tslpr-cd22免疫治疗来治疗癌症的组合物和方法
|
WO2022093745A1
(en)
|
2020-10-26 |
2022-05-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting sars coronavirus spike protein and uses thereof
|
CA3171093A1
(en)
|
2020-11-05 |
2022-05-12 |
Dina SCHNEIDER |
Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
|
CA3200974A1
(en)
|
2020-11-08 |
2022-05-12 |
Seagen Inc. |
Combination therapy
|
CA3212665A1
(en)
|
2021-03-09 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
KR20230154311A
(ko)
|
2021-03-10 |
2023-11-07 |
젠코어 인코포레이티드 |
Cd3 및 gpc3에 결합하는 이종이량체 항체
|
EP4319820A1
(en)
|
2021-04-10 |
2024-02-14 |
Profoundbio Us Co. |
Folr1 binding agents, conjugates thereof and methods of using the same
|
CA3216459A1
(en)
|
2021-04-23 |
2022-10-27 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
US20240218055A1
(en)
|
2021-04-29 |
2024-07-04 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Lassa virus-specific nanobodies and methods of their use
|
IL308351A
(en)
|
2021-05-12 |
2024-01-01 |
Genentech Inc |
Methods for using anti-CD79B immunoconjugates to treat diffuse large B-cell lymphoma
|
CN117396513A
(zh)
|
2021-05-28 |
2024-01-12 |
葛兰素史密斯克莱知识产权发展有限公司 |
治疗癌症的联合疗法
|
CN117500831A
(zh)
|
2021-06-09 |
2024-02-02 |
美国政府(由卫生和人类服务部的部长所代表) |
用于治疗实体瘤的靶向pd-l1的跨物种单结构域抗体
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
US11807685B2
(en)
|
2021-08-05 |
2023-11-07 |
The Uab Research Foundation |
Anti-CD47 antibody and uses thereof
|
US20240336697A1
(en)
|
2021-08-07 |
2024-10-10 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
CN118339280A
(zh)
|
2021-09-06 |
2024-07-12 |
维拉克萨生物技术有限责任公司 |
用于真核生物中遗传密码子扩展的新型氨酰tRNA合成酶变体
|
WO2023057893A1
(en)
|
2021-10-05 |
2023-04-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapies for treating cancer
|
WO2022078524A2
(en)
|
2021-11-03 |
2022-04-21 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation of an antibody
|
TW202333797A
(zh)
|
2021-11-05 |
2023-09-01 |
法商賽諾菲公司 |
含有抗ceacam5抗體-藥物接合物及抗vegfr-2抗體之抗腫瘤組合
|
US20250073346A1
(en)
|
2021-11-18 |
2025-03-06 |
Oxford Bio Therapeutics Ltd |
Pharmaceutical combinations
|
WO2023092099A1
(en)
|
2021-11-19 |
2023-05-25 |
Ardeagen Corporation |
Gpc3 binding agents, conjugates thereof and methods of using the same
|
EP4186529B1
(en)
|
2021-11-25 |
2025-07-09 |
Veraxa Biotech GmbH |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
AU2022395626A1
(en)
|
2021-11-25 |
2024-05-30 |
Veraxa Biotech Gmbh |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
EP4440618A1
(en)
|
2021-12-02 |
2024-10-09 |
Sanofi |
Ceacam5 adc-anti-pd1/pd-l1 combination therapy
|
AU2022400237A1
(en)
|
2021-12-02 |
2024-07-18 |
Sanofi |
Cea assay for patient selection in cancer therapy
|
US20250135011A1
(en)
|
2021-12-08 |
2025-05-01 |
European Molecular Biology Laboratory |
Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
|
EP4448015A1
(en)
|
2021-12-15 |
2024-10-23 |
The Administrators of The Tulane Educational Fund |
Conjugates, their compositions, and their related methods
|
AU2023221765B2
(en)
|
2022-02-15 |
2024-09-19 |
Tagworks Pharmaceuticals B.V. |
Masked il12 protein
|
US11590169B1
(en)
|
2022-03-02 |
2023-02-28 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD123 immunotherapy
|
US20230338424A1
(en)
|
2022-03-02 |
2023-10-26 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
|
KR20250049569A
(ko)
|
2022-07-15 |
2025-04-11 |
페온 테라퓨틱스 리미티드 |
항체-약물 접합체
|
JP2025526420A
(ja)
|
2022-07-28 |
2025-08-13 |
レンティジェン・テクノロジー・インコーポレイテッド |
固形腫瘍を処置するためのキメラ抗原受容体治療
|
AU2023329412A1
(en)
|
2022-08-26 |
2025-03-20 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with fully human anti-cd20/cd19 immunotherapy
|
AU2023358214A1
(en)
|
2022-10-12 |
2025-05-08 |
Tagworks Pharmaceuticals B.V. |
Strained bicyclononenes
|
WO2024153789A1
(en)
|
2023-01-20 |
2024-07-25 |
Basf Se |
Stabilized biopolymer composition, their manufacture and use
|
WO2024180192A1
(en)
|
2023-03-01 |
2024-09-06 |
Sanofi |
Use of anti-ceacam5 immunoconjugates for treating neuroendocrine cancers expressing ceacam5
|
EP4427763A1
(en)
|
2023-03-06 |
2024-09-11 |
Sanofi |
Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies
|
WO2024191293A1
(en)
|
2023-03-10 |
2024-09-19 |
Tagworks Pharmaceuticals B.V. |
Trans-cyclooctene with improved t-linker
|
TW202500194A
(zh)
|
2023-03-23 |
2025-01-01 |
法商賽諾菲公司 |
用於癌症治療中患者選擇之CEACAM5 mRNA分析
|
WO2024218345A1
(en)
|
2023-04-21 |
2024-10-24 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies
|
TW202513094A
(zh)
|
2023-06-05 |
2025-04-01 |
法商賽諾菲公司 |
含有抗ceacam5抗體藥物接合物、抗pd1/pd-l1抗體及抗ctla4抗體之抗腫瘤組合
|
WO2024254455A1
(en)
|
2023-06-08 |
2024-12-12 |
Genentech, Inc. |
Macrophage signatures for diagnostic and therapeutic methods for lymphoma
|
WO2025014896A1
(en)
|
2023-07-07 |
2025-01-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Humanized 40h3 antibody
|
WO2025019228A1
(en)
|
2023-07-20 |
2025-01-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
|
WO2025021929A1
(en)
|
2023-07-27 |
2025-01-30 |
Veraxa Biotech Gmbh |
Hydrophilic trans-cyclooctene (hytco) compounds, constructs and conjugates containing the same
|
WO2025056807A1
(en)
|
2023-09-15 |
2025-03-20 |
Basf Se |
Stabilized biopolymer composition, their manufacture and use
|
WO2025072406A1
(en)
|
2023-09-26 |
2025-04-03 |
Profoundbio Us Co. |
Ptk7 binding agents, conjugates thereof and methods of using the same
|
WO2025094146A1
(en)
|
2023-11-02 |
2025-05-08 |
Immunogen Switzerland Gmbh |
Vasconstrictors for reducing ocular toxicity of antibody-maytansinoid conjugates
|
WO2025149661A1
(en)
|
2024-01-10 |
2025-07-17 |
Genmab A/S |
Slitrk6 binding agents, conjugates thereof and methods of using the same
|
WO2025149667A1
(en)
|
2024-01-12 |
2025-07-17 |
Pheon Therapeutics Ltd |
Antibody drug conjugates and uses thereof
|
WO2025169012A1
(en)
|
2024-02-06 |
2025-08-14 |
Sanofi |
Methods of treating ceacam5-expressing cancers
|
WO2025171238A1
(en)
|
2024-02-07 |
2025-08-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof
|
WO2025174248A1
(en)
|
2024-02-16 |
2025-08-21 |
Tagworks Pharmaceuticals B.V. |
Trans-cyclooctenes with "or gate" release
|
WO2025181219A1
(en)
|
2024-02-29 |
2025-09-04 |
Genmab A/S |
Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
|